Page 79 - GTM-1-1

Global Translational Medicine ctDNA in management of patients with NSCLC

35. Valihrach L, Androvic P, Kubista M, 2020, Circulating https://doi.org/10.1101/gr.242719.118
miRNA analysis for cancer diagnostics and therapy. Mol 47. Snyder MW, Kircher M, Hill AJ, et al., 2016, Cell-free DNA
Aspects Med, 72: 100825.
comprises an in vivo nucleosome footprint that informs its
https://doi.org/10.1016/j.mam.2019.10.002 tissues-of-origin. Cell, 164(1-2): 57–68.
36. Oudkerk M, Liu S, Heuvelmans MA, et al., 2021, Lung cancer https://doi.org/10.1016/j.cell.2015.11.050
LDCT screening and mortality reduction evidence, pitfalls
and future perspectives. Nat Rev Clin Oncol, 18(3): 135–151. 48. Liu MC, Oxnard GR, Klein EA, et al., 2020, Sensitive and specific
multi-cancer detection and localization using methylation
https://doi.org/10.1038/s41571-020-00432-6 signatures in cell-free DNA. Ann Oncol, 31(6): 745–759.
37. Aberle DR, Adams AM, Berg CD, et al., 2011, Reduced lung- https://doi.org/10.1016/j.annonc.2020.02.011
cancer mortality with low-dose computed tomographic
screening. N Engl J Med, 365(5): 395–409. 49. Chen C, Huang X, Yin W, et al., 2020, Ultrasensitive DNA
hypermethylation detection using plasma for early detection
38. de Koning HJ, van der Aalst CM, de Jong PA, et al., 2020, of NSCLC: A study in Chinese patients with very small
Reduced lung-cancer mortality with volume CT screening nodules. Clin Epigenetics, 12(1): 39.
in a randomized trial. N Engl J Med, 382(6): 503–513.
https://doi.org/10.1186/s13148-020-00828-2
https://doi.org/10.1056/NEJMoa1911793
50. Shen SY, Singhania R, Fehringer G, et al., 2018, Sensitive
39. Hoffman RM, Atallah RP, Struble RD, et al., 2020, Lung tumour detection and classification using plasma cell-free
cancer screening with low-dose CT: A meta-analysis. J Gen DNA methylomes. Nature, 563(7732): 579–583.
Intern Med, 35(10): 3015–3025.
https://doi.org/10.1038/s41586-018-0703-0
https://doi.org/10.1007/s11606-020-05951-7
51. Qi J, Hong B, Tao R, et al., 2021, Prediction model for
40. Perisinakis K, Seimenis I, Tzedakis A, et al., 2018, Radiation malignant pulmonary nodules based on cfMeDIP-seq and
burden and associated cancer risk for a typical population to machine learning. Cancer Sci, 112(9): 3918–3923.
be screened for lung cancer with low-dose CT: A phantom
study. Eur Radiol, 28(10): 4370–4378. https://doi.org/10.1111/cas.15052
https://doi.org/10.1007/s00330-018-5373-7 52. Kumar S, Paiva B, Anderson KC, et al., 2016, International
myeloma working group consensus criteria for response and
41. Cohen JD, Li L, Wang Y, et al., 2018, Detection and minimal residual disease assessment in multiple myeloma.
localization of surgically resectable cancers with a multi-
analyte blood test. Science, 359(6378): 926–930. Lancet Oncol, 17(8): e328–e346.
https://doi.org/10.1016/S1470-2045(16)30206-6
https://doi.org/10.1126/science.aar3247
53. Cescon DW, Bratman SV, Chan SM, et al., 2020, Circulating
42. Newman AM, Bratman SV, To J, et al., 2014, An ultrasensitive
method for quantitating circulating tumor DNA with broad tumor DNA and liquid biopsy in oncology. Nat Cancer, 1(3):
patient coverage. Nat Med, 20(5): 548–554. 276–290.
https://doi.org/10.1038/nm.3519 https://doi.org/10.1038/s43018-020-0043-5
43. Chabon JJ, Hamilton EG, Kurtz DM, et al., 2020, Integrating 54. Di Capua D, Bracken-Clarke D, Ronan K, et al., 2021, The
genomic features for non-invasive early lung cancer liquid biopsy for lung cancer: state of the art, limitations and
detection. Nature, 580(7802): 245–251. future developments. Cancers (Basel), 13(16): 3923.
https://doi.org/10.1038/s41586-020-2140-0 https://doi.org/10.3390/cancers13163923
44. Mathios D, Johansen JS, Cristiano S, et al., 2021, Detection 55. Chin RI, Chen K, Usmani A, et al., 2019, Detection of solid
and characterization of lung cancer using cell-free DNA tumor molecular residual disease (MRD) using circulating
fragmentomes. Nat Commun, 12(1): 5060. tumor DNA (ctDNA). Mol Diagn Ther, 23(3): 311–331.
https://doi.org/10.1038/s41467-021-24994-w https://doi.org/10.1007/s40291-019-00390-5
45. Mouliere F, Chandrananda D, Piskorz AM, et al., 2018, 56. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al., 2017, Early
Enhanced detection of circulating tumor DNA by fragment detection of molecular residual disease in localized lung
size analysis. Sci Transl Med, 10(466): eaat4921. cancer by circulating tumor DNA profiling. Cancer Discov,
7(12): 1394–1403.
https://doi.org/10.1126/scitranslmed.aat4921
https://doi.org/10.1158 / 2159-8290.CD-17-0716
46. Sun K, Jiang P, Cheng SH, et al., 2019, Orientation-aware
plasma cell-free DNA fragmentation analysis in open 57. Chen K, Sun J, Zhao H, et al., 2021, Non-invasive lung
chromatin regions informs tissue of origin. Genome Res, cancer diagnosis and prognosis based on multi-analyte
29(3): 418–427. liquid biopsy. Mol Cancer, 20(1): 23.

Volume 1 Issue 1 (2022) 12 https://doi.org/10.36922/gtm.v1i1.96